Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PHAT
PHATHOM PHARMACEUTICALS, INC.
NASDAQ
$9.18
▲ UP 2.68% (0.24)

KEY STATISTICS

Market Cap$742.67 M
52w High$18.31
52w Low$8.21
Dividend Yield—
Frequency—
P/E-7.17
Volume893.30K
Shares Out.80.90M

COMPANY

LEADERSHIP

Steven L. Basta
CHIEF EXECUTIVE
Steven L. Basta

COMPENSATION 2026

Salary$184,000
Stock Awards$473,472
Incentive Plan Pay$0
All Other Comp.$2,834,106
Total$4,936,791

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 25, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
371

PRICE TARGET

Target High$22.00
Target Low$14.00
Target Median$21.00
Target Consensus$19.50

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.$85.42M
OCT
29
THU

PRICE

$9.18 ▲ UP 2.68% (+$0.24)
$8.85$9.00$9.15$9.309:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM9.18

About Phathom Pharmaceuticals, Inc.

https://www.phathompharma.com ↗

Phathom Pharmaceuticals, a clinical-stage biopharma founded in 2018 in New Jersey, develops treatments for GI diseases, including vonoprazan, a P-CAB in Phase III trials for reflux and H. pylori.

INDUSTRY

Biotechnology

A PRODUCT PHATHOM PHARMACEUTICALS, INC. IS KNOWN FOR

VOQUEZNA® (vonoprazan)
VOQUEZNA® (vonoprazan)

VOQUEZNA® (vonoprazan) is a first-in-class potassium-competitive acid blocker approved for GERD, H. pylori infection, and heartburn relief, representing a major innovation in gastrointestinal treatment in the U.S.

COMPETITORS

COMPETITOR
AZN COMPARE
JNJ COMPARE
PFE COMPARE
RDHL COMPARE
TAK COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
102
LISTED HERE
16
RANKED BY POSITION SIZE
VTI
0.00% · 2.0M
XSU.TO
0.01% · 1.3M
XPH
0.82% · 535.5K
SURI
2.63% · 249.3K
SCHA
0.01% · 244.9K
BBP
1.06% · 141.2K
GSSC
0.07% · 83.9K
XRSU.L
0.01% · 45.0K
RSSL
0.01% · 23.3K
FHLC
0.01% · 22.8K
PILL
0.55% · 15.1K
IBBQ
0.04% · 5.0K
BIB
0.03% · 2.9K
PQ
PQSG
0.17% · 736
USFMDN.MX
0.00% · 216
AVTM
0.00% · 208

INSTITUTIONAL OWNERSHIP

SHARES OWNED
64.40%
HOLDERS
240
TOP 12 OF 240 · RANKED BY POSITION SIZE
Frazier Life Sciences Management, L.P.
12.5M sh · $146.73M
Medicxi Ventures Management (Jersey) Ltd
7.5M sh · $82.93M
Millennium Management LLC
5.1M sh · $59.81M
Blackrock, Inc.
4.5M sh · $49.1M
Invesco Ltd.
4.3M sh · $48.02M
Carlyle Group Inc.
3.5M sh · $37.94M
Vanguard Group Inc
3.2M sh · $37.85M
Blackrock Inc.
2.9M sh · $30.14M
Ensign Peak Advisors, Inc
2.5M sh · $29.46M
Gw&K Investment Management, LLC
2.2M sh · $23.51M
Franklin Resources Inc
2.0M sh · $21.38M
Nea Management Company, LLC
2.0M sh · $21.27M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: PRINCIPAL ACCOUNTING OFFICER
Breedlove Robert Charles
Sale · 1.6K shares
2026-07-14
★
DIRECTOR
Parikh Asit
Purchase · 28.0K shares
2026-05-22
★
DIRECTOR
COLA MICHAEL F
Purchase · 24.1K shares
2026-05-19
★
DIRECTOR
KARBE FRANK
Purchase · 24.1K shares
2026-05-19

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OVERWEIGHT 1
4 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT Guggenheim BUY HC Wainwright & Co. BUY Needham BUY

SECTORS PEERS

PEERPRICE
NRIX$26.21COMPARE
KOD$37.72COMPARE
URGN$43.62COMPARE
XNCR$26.06COMPARE
SEPN$38.91COMPARE
ANAB$56.28COMPARE
BCAX$23.43COMPARE
SANA$3.93COMPARE